SCHEMBL5330644

SCHEMBL5330644

OCCc1cccc2c1OC(F)(F)O2

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.40
ADORA2A P29274 3/20 0.37
DRD2 P14416 2/20 0.36
DRD1 P21728 1/20 0.36
FFAR4 Q5NUL3 1/20 0.33
RORC P51449 3/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
CTNNB1 P35222 1/20 0.32
WNT3A P56704 1/20 0.32
AKT1 P31749 2/20 0.31
IDO1 P14902 1/20 0.31
HTR1A P08908 1/20 0.31
HTR2A P28223 1/20 0.31
CETP P11597 1/20 0.31
MTNR1A P48039 1/20 0.31
ATR Q13535 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7651499 0.86 MPO (0.41) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL34462978 0.83 MPO (0.43) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL34463082 0.83 MPO (0.43) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL7274441 0.80 MPO (0.42) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL3288378 0.79 MPO (0.44) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL2663368 0.79 MPO (0.41) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL5323473 0.77 RORC (0.44) MPOADORA2AFFAR4RORCCTNNB1
SCHEMBL8886606 0.76 ADORA2A (0.42) MPOADORA2ADRD2DRD1FFAR4
SCHEMBL9701947 0.75 MTNR1A (0.43) MPOADORA2ADRD2FFAR4CTNNB1
SCHEMBL23835067 0.75 MPO (0.39) MPOADORA2ADRD2DRD1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MPO 464/4885ADORA2A 4665/4885DRD2 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.